US HEALTHCARE & LIFE SCIENCES CONFERENCE
Financial Times, in Association with Deloitte
The University Club of New York
Wednesday, June 6, 2012
Panel (6 June 2012, 3:00 - 4:00 p.m.)
The Right Medicine for the Right Person at the Right Time
Delivering on the Potential and Promise of Personalized Medicine
Some ten years after the unravelling of the human genome, important inroads are being made in realizing the vision of personalized medicine. Life sciences companies are waking up to the potential of personalized medicine to produce drugs more cheaply and efficiently, to avoid adverse drug reaction and related litigation, and to satisfy risk adverse watchdogs who are lifting the barriers for the approval and reimbursement of new drugs. Yet many remain to be convinced of the underlying business case for such a radical move away from the traditional industry blockbuster models to one based on smaller patient sub-populations. Many barriers remain – regulator, client and payor acceptability – before the vision of personalized medicine can be realized. What are the commercial models and strategies for personalized medicine?
- John Crowley, Chairman and Chief Executive Officer, Amicus Therapeutics
- Geno Germano, President and General Manager, Specialty Care and Oncology, Pfizer Inc.
- Nancy J. Kelley, JD, MPP, Founding Executive Director, New York Genome Center
- Edward Michael, Executive Vice President, Diagnostics, Abbott Laboratories
- Andrew Jack, Pharmaceuticals Correspondent, Financial Times
For more information and to register, please visit FT Global Conferences & Events.